The Swedish medical technology firm saw a significant uptick in adoption, with electrode sales volume jumping 118% to 40,144 units during the quarter. This growth was bolstered by an 80% increase in U.S. skin cancer market sales and a substantial expansion in the skin barrier segment. While the gross margin dipped to 52.6%—largely due to currency fluctuations, rising gold prices, and ongoing product deliveries for Castle Biosciences—the company maintains that underlying margins remain near 70% when these factors are stripped away.

Looking beyond the current financials, SciBase is moving to broaden its regulatory reach. The company recently submitted a 510(k) premarket notification to the U.S. Food and Drug Administration, seeking to expand the indication for Nevisense to include non-melanoma skin cancers. Simultaneously, clinical momentum continues as the company reached a milestone of 400,000 tests sold globally and initiated a new study focused on atopic dermatitis flare prediction.